PROTAb-0001

PROTAb-0001 is a preclinical drug candidate developed by Orum Therapeutics. It is an antibody-drug conjugate (ADC) that utilizes the proprietary PROTAb platform, which enables targeted protein degradation through the conjugation of a protein degrader to a monoclonal antibody. The platform is designed to deliver catalytic degraders specifically to tumor cells, thereby degrading disease-driving proteins rather than merely inhibiting them. This approach aims to overcome limitations of traditional small-molecule inhibitors and ADCs by providing both tissue specificity and potent, sustained target knockdown. The primary therapeutic area for PROTAb-0001 is neoplasms (cancer), but specific targets and indications have not been publicly disclosed[1][2][5][7].